Imricor Medical Systems (ASX:IMR) said that its Advantage-MR electrophysiology recording and cardiac stimulator system received CE mark certification under the European Union's new medical device regulations regime, according to a Thursday Australian bourse filing.

The commercial launch of its second-generation Vision-MR ablation catheter and the new Advantage-MR system is planned to start in June across new and existing sites in the EU.

In February, the company's second-generation Vision-MR ablation catheter received CE mark approval under the medical device regulations regime.

Imricor's shares fell almost 4% in recent trading on Thursday.